Atyr PHARMA (ATYR) to Release Earnings on Thursday

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) will likely be announcing its Q1 2025 earnings results before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of ($0.19) per share for the quarter.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last issued its earnings results on Thursday, March 13th. The company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.05. On average, analysts expect Atyr PHARMA to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Atyr PHARMA Price Performance

Shares of NASDAQ:ATYR traded down $0.13 during trading on Thursday, hitting $3.34. 1,042,945 shares of the company were exchanged, compared to its average volume of 903,035. Atyr PHARMA has a 1-year low of $1.42 and a 1-year high of $4.66. The company has a market capitalization of $296.79 million, a P/E ratio of -3.55 and a beta of 0.95. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. The business's 50 day moving average is $3.31 and its 200-day moving average is $3.38.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ATYR. HC Wainwright reissued a "buy" rating and set a $35.00 price target on shares of Atyr PHARMA in a research note on Friday, March 14th. Leerink Partnrs upgraded shares of Atyr PHARMA to a "strong-buy" rating in a report on Tuesday, February 18th. Leerink Partners initiated coverage on Atyr PHARMA in a report on Tuesday, February 18th. They issued an "outperform" rating and a $16.00 price objective for the company. Finally, Cantor Fitzgerald initiated coverage on Atyr PHARMA in a report on Monday, January 6th. They set an "overweight" rating on the stock. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $18.60.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.